Alzheon to Present at the 22nd Annual NewsMakers in the Biotech Industry Conference
FRAMINGHAM, Mass.–(BUSINESS WIRE)–Alzheon, Inc., a clinical-stage biopharmaceutical company focused on
developing new medicines for patients suffering from Alzheimer’s disease
and other neurological and psychiatric disorders, today announced that
Martin Tolar, M.D., Ph.D., Founder, President and Chief Executive
Officer, will present at the 22nd Annual NewsMakers in the
Biotech Industry Conference at the Millennium Broadway Hotel on
Thursday, September 10, 2015 at 10:30 a.m. Eastern Time in New York, NY.
About Alzheon
Alzheon, Inc. is committed to developing innovative medicines for
patients suffering from Alzheimer’s disease and other neurological and
psychiatric disorders. Our lead clinical candidate, ALZ-801, is a
first-in-class, oral inhibitor of amyloid aggregation and neurotoxicity
– hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel
prodrug that builds on the established safety and efficacy profile of
the active compound in clinical trials of more than 2,000 patients. Our
mission is to apply our discovery platform and development experience to
unlock new classes of therapeutics that make a difference in patients’
lives by directly addressing the underlying pathology of devastating
neurodegenerative disorders. www.alzheon.com
Contacts
MacDougall Biomedical Communications
Douglas MacDougall
781-235-3060
dmacdougall@macbiocom.com
